All In Biotech

Drug Trial Radar · NCT02536937

A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function

Last checked: Nov 19, 2026Latest source record: Mar 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Sep 2015

Primary completion

Jan 2017

Study completion Jan 2017

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: To study the effect of mild, moderate, and severe renal impairment on the pharmacokinetics (PK) of eliglustat. Secondary Objective: To assess the tolerability of eliglustat tartrate given as a single dose in subjects with mild, moderate, and severe renal impairment in comparison with matched subjects with normal renal function.

Conditions

  • Gaucher Disease

Interventions

  • eliglustatDrug

    Pharmaceutical form: capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - Assessment of PK parameter: Maximum plasma concentration observed (Cmax)Time frame: 3 days
  2. - Assessment of PK parameter: Area under the plasma concentration (AUC)Time frame: 3 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 840004

    Miami, Florida

  • Investigational Site Number 840002

    Saint Paul, Minnesota

  • Investigational Site Number 840001

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.